Literature DB >> 25196606

Regression of solid tumors by induction of MazF, a bacterial mRNA endoribonuclease.

Tsutomu Shimazu1, Oleg Mirochnitchenko, Sangita Phadtare, Masayori Inouye.   

Abstract

MazF from Escherichia coli is an endoribonuclease that specifically cleaves mRNAs at ACA sequences. Its induction in mammalian cells has been shown to cause programmed cell death. Here we explored if a bacterial MazF-MazE toxin-antitoxin system can be used for gene therapy. For this, we first constructed a tetracycline-inducible MazF expression system in human embryonic kidney cells (T-Rex 293-mazF). Solid tumors were formed by injecting T-Rex 293-mazF cells into nude mice. All 8 mice injected with the cells developed solid tumors, which regressed upon induction of MazF. In 4 mice, tumors completely regressed, while in the remaining 4 mice, tumors reappeared after apparent significant regression, which was found to be due to the lack of presence of functional MazF. Notably, the MazF-mediated regression of the tumors was counteracted by the expression of its cognate antitoxin MazE. These results indicate that a bacterial MazF-MazE toxin-antitoxin system may have potential to be used as a therapeutic tool.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25196606     DOI: 10.1159/000365509

Source DB:  PubMed          Journal:  J Mol Microbiol Biotechnol        ISSN: 1464-1801


  8 in total

Review 1.  Tumor vascular infarction: prospects and challenges.

Authors:  Rana Jahanban-Esfahlan; Khaled Seidi; Nosratollah Zarghami
Journal:  Int J Hematol       Date:  2017-01-02       Impact factor: 2.490

Review 2.  Toxin-antitoxin systems and their medical applications: current status and future perspective.

Authors:  Akriti Srivastava; Soumya Pati; Himani Kaushik; Shailja Singh; Lalit C Garg
Journal:  Appl Microbiol Biotechnol       Date:  2021-02-13       Impact factor: 4.813

Review 3.  Biology and evolution of bacterial toxin-antitoxin systems.

Authors:  Dukas Jurėnas; Nathan Fraikin; Frédéric Goormaghtigh; Laurence Van Melderen
Journal:  Nat Rev Microbiol       Date:  2022-01-02       Impact factor: 60.633

Review 4.  One cannot rule them all: Are bacterial toxins-antitoxins druggable?

Authors:  Wai Ting Chan; Dolors Balsa; Manuel Espinosa
Journal:  FEMS Microbiol Rev       Date:  2015-03-21       Impact factor: 16.408

5.  Selective eradication of cancer cells by delivery of adenovirus-based toxins.

Authors:  Shiran Shapira; Assaf Shapira; Diana Kazanov; Gil Hevroni; Sarah Kraus; Nadir Arber
Journal:  Oncotarget       Date:  2017-06-13

6.  A Systematic Overview of Type II and III Toxin-Antitoxin Systems with a Focus on Druggability.

Authors:  Sung-Min Kang; Do-Hee Kim; Chenglong Jin; Bong-Jin Lee
Journal:  Toxins (Basel)       Date:  2018-12-04       Impact factor: 4.546

Review 7.  Keeping the Wolves at Bay: Antitoxins of Prokaryotic Type II Toxin-Antitoxin Systems.

Authors:  Wai Ting Chan; Manuel Espinosa; Chew Chieng Yeo
Journal:  Front Mol Biosci       Date:  2016-03-22

Review 8.  Targeting Type II Toxin-Antitoxin Systems as Antibacterial Strategies.

Authors:  Marcin Równicki; Robert Lasek; Joanna Trylska; Dariusz Bartosik
Journal:  Toxins (Basel)       Date:  2020-09-04       Impact factor: 4.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.